ATAI Life Sciences NV (NAS:ATAI)

$ 1.54 -0.07 (-4.35%) Market Cap: 257.81 Mil Enterprise Value: 182.75 Mil PE Ratio: 0 PB Ratio: 1.15 GF Score: 17/100

ATAI Life Sciences NV Announces Strategic Investment in Beckley Psytech Ltd Call Transcript
Jan 04, 2024
Q3 2022 ATAI Life Sciences NV Earnings Presentation Transcript
Nov 10, 2022
ATAI Life Sciences NV R&D Investor Day Transcript
Oct 25, 2022
ATAI Life Sciences NV at Citi BioPharma Conference Transcript
Sep 07, 2022
Q2 2022 ATAI Life Sciences NV Earnings Presentation Transcript
Aug 15, 2022
ATAI Life Sciences NV at Citi Biopharma Co-Panel Day (Virtual) Transcript
May 18, 2022
Q1 2022 ATAI Life Sciences NV Earnings Call Transcript
May 16, 2022

$4.04 (+10.99%)

Earnings
Q4 2021 ATAI Life Sciences NV Earnings Call Transcript
Mar 30, 2022

$5.34 (-1.48%)

Earnings
ATAI Life Sciences NV at Citi Winter Biotech Virtual Bus Tour Transcript
Mar 22, 2022
Atai Life Sciences N.V. - Special Call Transcript
Jan 18, 2022
Q3 2021 ATAI Life Sciences NV Earnings Call Transcript
Nov 15, 2021

$12.85 (-13.87%)

Earnings
ATAI Life Sciences NV at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 11, 2021
ATAI Life Sciences NV at Citi BioPharma Conference (Virtual) Transcript
Sep 08, 2021

ATAI Life Sciences NV R&D Investor Day Transcript

Oct 25, 2022 / 04:00PM GMT

Release Date Price: $3.02 (+4.50%)

Transcript

Florian Brand

Atai Life Sciences N.V. - Co-founder & CEO

Good morning, everyone. I'm Florian Brand, the Co-Founder and CEO of atai Life Sciences, and it's a pleasure to welcome you today to our R&D Day.

We have an incredible agenda today, and we'll hear from industry key opinion leaders and some of our own senior R&D team. To kick things off, I'll walk you through our founding story and how we anticipate making a positive impact for mental health patients. Then we will deep dive into one of our key indications, treatment-resistant depression, or TRD.

We'll start with an engaging fireside chat hosted by Dr. Heather Berlin, in which he will discuss the clinical and regulatory aspects of TRD with Dr. Gerard Sanacora and Heddie Martynowicz.

Then our Co-Founder and Chief Scientific Officer, Dr. Srinivas Rao, will discuss PCN-101, our R-ketamine program in TRD. This program has a Phase IIa readout coming up around the end of this year. Srini will focus on contextualizing this specific upcoming dataset. He will then briefly discuss COMP360, a psilocybin therapy program

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.